Kestra Advisory Services’s Novavax NVAX Stock Holding History

Kestra Advisory Services’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,946	Closed	-$659K	–	2214
2022 Q1	$659K	Sell	8,946 -4,585	-34%	-$409K	0.01%	1133
2021 Q4	$1.94M	Buy	13,531 +658	+5%	+$113K	0.02%	692
2021 Q3	$2.67M	Buy	12,873 +3,273	+34%	+$721K	0.03%	595
2021 Q2	$2.04M	Buy	9,600 +5,831	+155%	+$1.07M	0.02%	644
2021 Q1	$683K	Buy	3,769 +760	+25%	+$151K	0.01%	1043
2020 Q4	$358K	Buy	+3,009	New	+$320K	﹤0.01%	1373

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kestra Advisory Services's NVAX Position: Q2 2022 in Review

Kestra Advisory Services sold out of Novavax (NVAX) in Q2 2022, closing a stake of 8,946 shares — an estimated $659K sold.

Kestra Advisory Services first reported a position in NVAX in Q4 2020 and held it in 6 quarters. The position peaked at $2.67M in Q3 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Kestra Advisory Services reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Kestra Advisory Services sold 8,946 Novavax shares in Q2 2022, an estimated $659K.
Kestra Advisory Services first reported a position in Novavax in Q4 2020 and held it in 6 quarters.
Kestra Advisory Services's Novavax position peaked at $2.67M in Q3 2021.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Kestra Advisory Services's 13F filing for Q2 2022, filed 12 Aug 2022.